SCHEMBL2656884

SCHEMBL2656884

CCC(N)(CC)c1cccc(-c2cc(C#N)cc3ncn(-c4ccccc4)c23)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 7/20 0.41
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
MET P08581 1/20 0.35
PLK1 P53350 1/20 0.34
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32
GFER P55789 1/20 0.32
SRC P12931 1/20 0.32
DPP4 P27487 1/20 0.32
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
LRRK2 Q5S007 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3537552 0.93 PLK1 (0.39) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2657491 0.82 FGFR1 (0.45) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2654095 0.81 FGFR1 (0.44) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2656607 0.80 FGFR1 (0.46) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2656885 0.79 FGFR1 (0.42) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2654061 0.79 FGFR1 (0.43) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2656918 0.79 FGFR1 (0.42) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2656906 0.79 FGFR1 (0.51) FGFR1ALDH1A1HTTGFERSRC
SCHEMBL2654894 0.77 FGFR1 (0.44) FGFR1METALDH1A1HTTSRC
SCHEMBL2655351 0.77 FGFR1 (0.39) FGFR1GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700638-B2 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex N. V. ORGANON (NL) 2010-04-20 US claimed
JP-2007509108-A 2007-04-12 JP claimed
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex N.V. ORGANON (NL) 2007-01-25 US claimed
EP-1678144-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX Akzo Nobel N.V. (NL) 2006-07-12 EP claimed
WO-2005040131-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX AKZO NOBEL N.V. (NL) 2005-05-06 WO claimed
US-7700638-B2 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex N. V. ORGANON (NL) 2010-04-20 US disclosed
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex N.V. ORGANON (NL) 2007-01-25 US disclosed
EP-1678144-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX Akzo Nobel N.V. (NL) 2006-07-12 EP disclosed
WO-2005040131-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX AKZO NOBEL N.V. (NL) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex GABRB1, GABRA5, GABRB2 FGFR1 2259/4885GABRA1 5/4885GABRG2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.